SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

OneSource Specialty Pharma shines on securing EU GMP certificate for SPD facility

29 Apr 2026 Evaluate

Onesource Specialty Pharma is currently trading at Rs. 1816.70, up by 54.20 points or 3.08% from its previous closing of Rs. 1762.50 on the BSE.

The scrip opened at Rs. 1840.10 and has touched a high and low of Rs. 1840.15 and Rs. 1792.50 respectively. So far 8115 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2249.65 on 18-Jun-2025 and a 52 week low of Rs. 1075.00 on 30-Jan-2026.

Last one week high and low of the scrip stood at Rs. 1870.00 and Rs. 1323.15 respectively. The current market cap of the company is Rs. 20858.08 crore.

The promoters holding in the company stood at 30.48%, while Institutions and Non-Institutions held 38.11% and 31.41% respectively.

OneSource Specialty Pharma has received an EU GMP Certificate of Compliance of a Manufacturer for its Sterile Product Division (SPD) facility from the competent German authority, the State Office for Occupational Safety, Social Affairs and Health of Schleswig-Holstein, Germany. The certificate, dated April 27, 2026, was issued following the latest inspection conducted on October 14, 2025, and confirms compliance with EU GMP requirements for sterile products. The certificate covers sterile products, including aseptically prepared small volume liquids, secondary packing and quality control testing.

Separately, the Sterile Product Division has capabilities across liquid vials, lyophilised vials, pre-filled syringes and autoinjectors, and holds approvals from US-FDA, Health Canada, ANVISA and TGA.

OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.

Onesource Specialty Share Price

1801.90 -34.05 (-1.85%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×